Livforsakringsbolaget Skandia Omsesidigt Has $148,000 Position in Bristol-Myers Squibb (NYSE:BMY)

Livforsakringsbolaget Skandia Omsesidigt lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 96.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,568 shares of the biopharmaceutical company’s stock after selling 103,500 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Bristol-Myers Squibb were worth $148,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Northwest Financial Advisors acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $27,000. ESL Trust Services LLC acquired a new position in shares of Bristol-Myers Squibb in the first quarter valued at approximately $27,000. Accordant Advisory Group Inc acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $31,000. Pacific Capital Wealth Advisors Inc. acquired a new position in Bristol-Myers Squibb in the 4th quarter worth $34,000. Finally, Turtle Creek Wealth Advisors LLC bought a new position in Bristol-Myers Squibb during the 4th quarter worth about $40,000. 76.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. BMO Capital Markets reduced their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, July 23rd. TD Cowen raised their price objective on Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a report on Monday. Wells Fargo & Company increased their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Finally, Barclays cut Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 price objective on the stock. in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $54.86.

Bristol-Myers Squibb Trading Up 0.6 %

Shares of NYSE:BMY traded up $0.26 during midday trading on Monday, reaching $46.98. The company’s stock had a trading volume of 3,610,892 shares, compared to its average volume of 15,887,571. The firm has a market capitalization of $95.23 billion, a price-to-earnings ratio of -15.22, a PEG ratio of 12.51 and a beta of 0.44. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.41. The firm has a 50 day moving average price of $43.02 and a two-hundred day moving average price of $46.60. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. The company had revenue of $12.20 billion for the quarter, compared to the consensus estimate of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. Bristol-Myers Squibb’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.75 EPS. As a group, analysts forecast that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.11%. The ex-dividend date was Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.